Date | Price Target | Rating | Analyst |
---|---|---|---|
6/28/2024 | Neutral | Cantor Fitzgerald | |
6/11/2024 | $382.00 | Outperform | Wolfe Research |
4/22/2024 | $150.00 | Underperform | BofA Securities |
3/15/2024 | $155.00 → $270.00 | Sell → Neutral | B. Riley Securities |
3/6/2024 | $382.00 | Buy | Citigroup |
2/26/2024 | $155.00 | Neutral → Sell | B. Riley Securities |
12/20/2022 | $170.00 → $250.00 | Outperform | Oppenheimer |
12/19/2022 | Underperform → Mkt Perform | Raymond James |
Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as "MASH")Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved liver fibrosis and resolved NASH in patients with noncirrhotic NASH with moderate to advanced liver fibrosis Rezdiffra prescribing information does not include a liver biopsy requirement for diagnosisMadrigal conference call scheduled for March 14, 2024, at 5:15 pm ET CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced t
In MAESTRO-NASH, a 52-week serial liver biopsy Phase 3 study in more than 950 patients, resmetirom achieved both primary endpoints and potentially clinically meaningful effects with both daily oral doses, 80 mg and 100 mg, relative to placebo NASH resolution (ballooning of 0, inflammation of 0-1) and ≥2-point NAS reduction with no worsening of fibrosis (p<0.0001 at both doses)Fibrosis improvement by at least one stage with no worsening of NAS (p=0.0002 and <0.0001 at 80 and 100 mg, respectively) Potentially clinically meaningful LDL-lowering, a key secondary endpoint (p<0.0001)Multiple positive effects on NASH biomarkers and imaging Resmetirom was safe and well-tolerated in the MAESTRO
CONSHOHOCKEN, Pa., Dec. 18, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), plans to announce topline results from the Phase 3 MAESTRO-NASH study of resmetirom on Monday, December 19th, 2022. The schedule for the press release and conference call/webcast is as follows: • MAESTRO-NASH Press Release: December 19th, 2022 at 7:00 am EST• MAESTRO-NAFLD-1 Conference Call: December 19th, 2022 at 8:00 am EST To access the live webcast of the call with slides please visit the Investors section of Madrigal's website or click here. To access the call by phone, p
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral.
JMP Securities analyst Jonathan Wolleben maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Market Outperform and raises the price target from $381 to $385.
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Neutral rating.
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leader
CONSHOHOCKEN, Pa., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Ronald Filippo has been appointed Chief Information Officer. Mr. Filippo has more than 25 years of digital experience in the biopharmaceutical industry and was previously Senior Vice President Digital at Moderna, where he was responsible for technology leadership and digital transformation across core operations during the commercialization of the company's COVID-19 vaccine. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Ron's skillset and depth of
CONSHOHOCKEN, Pa., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that Carole Huntsman has been appointed Chief Commercial Officer. Ms. Huntsman was most recently Senior Vice President, Head of Specialty Care North America and U.S. Country Lead at Sanofi, where she directed 2,600 team members across multiple product launches in immunology, neurology, oncology, rare diseases, and rare blood disorders. This included executing the launch of Dupixent, a first-in-class therapy which has grown into an industry-leading medicine. In 2022,
Cantor Fitzgerald initiated coverage of Madrigal Pharmaceuticals with a rating of Neutral
Wolfe Research initiated coverage of Madrigal Pharmaceuticals with a rating of Outperform and set a new price target of $382.00
BofA Securities initiated coverage of Madrigal Pharmaceuticals with a rating of Underperform and set a new price target of $150.00
10-Q - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
8-K - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Filer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024 at 10:45 A.M. ET. The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events page. A replay of the webcast will be available after the event. About Madrigal PharmaceuticalsMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (r
Second-quarter 2024 net sales of $14.6 million Rezdiffra™ (resmetirom) coverage in place for more than 50 percent of commercial lives; less than 5 percent of Rezdiffra-covered lives require biopsyExpert guidelines recommend Rezdiffra as first-line therapy for patients with F2/F3 NASH/MASHPlans to directly commercialize resmetirom in Europe following EMA decision expected mid-year 2025Reports cash, cash equivalents, restricted cash and marketable securities of $1.1 billion at June 30, 2024Company to host conference call today, August 7, 2024, at 8 a.m. EDT CONSHOHOCKEN, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focuse
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024. Bill Sibold, Chief Executive Officer of Madrigal, stated, "Shannon is an outstanding leader who brings a wealth of expertise to her new role as General Counsel. She joined the Madrigal team in 2024 as Chief Compliance Officer and played an instrumental role guiding the company through a period of rapid growth. I feel privileged to be working with Shannon and the other members of our leader
SC 13D/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
SC 13G/A - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Subject)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)